Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 18/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | DRD2 | P14416 | 4/20 | 0.61 |
| ▸ | DRD3 | P35462 | 4/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2768536 | 1.00 | DRD4 (0.71) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL10319583 | 1.00 | DRD4 (0.71) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1502000 | 1.00 | DRD4 (0.71) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL10670770 | 0.98 | DRD4 (0.69) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8325714 | 0.91 | DRD4 (0.60) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7368320 | 0.91 | DRD4 (0.59) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7262675 | 0.88 | DRD4 (0.76) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4228489 | 0.86 | DRD4 (0.65) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8327024 | 0.86 | DRD4 (0.65) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4029420 | 0.86 | DRD4 (0.62) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3140298-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | Pfizer Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9328096-B2 | Tropomyosin-related kinase inhibitors | PFIZER INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150322043-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER (US) | 2015-11-12 | — | — | US | disclosed |
| WO-2015170218-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| EP-1324990-B1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LTD (GB) | 2014-10-29 | — | — | EP | disclosed |
| US-8071592-B2 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| WO-2011058478-A1 | SUBSTITUTED TRIAZOLOPYRIMIDINES AS PDE8 INHIBITORS | PFIZER INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011058478-A1 | SUBSTITUTED TRIAZOLOPYRIMIDINES AS PDE8 INHIBITORS | PFIZER INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20100184751-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | BALLELL-PAGES LLUIS | 2010-07-22 | — | — | US | disclosed |
| US-7732460-B2 | Heterocyclic compounds, their preparation and their use as antibacterials | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| US-20070185153-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-7101882-B2 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2006-09-05 | — | — | US | disclosed |
| US-20060079525-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | ANCLIFF RACHAEL A | 2006-04-13 | — | — | US | disclosed |
| US-20050222147-A1 | Process for the preparation of morpholine derivatives and intermediates therefore | GLAXO GROUP LIMITED (GB) | 2005-10-06 | — | — | US | disclosed |
| CN-1678594-A | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | GLAXO GROUP LTD (GB) | 2005-10-05 | — | — | CN | disclosed |
| US-20040058923-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | SMITHKLINE BEECHAM CORPORATION | 2004-03-25 | — | — | US | disclosed |
| EP-1324990-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002026722-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
| US-6221864-B1 | (S)-1-CYCLOPROPYL-1,4-DIHYDRO-7-(2-(N, N-DIMETHYLAMINOMETHYL)MORPHOLINO)-6-FLUORO-8-METHOXY-4-OXOQUIN OLINE-3-CARB OXYLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; ANTISECRETORY DRUG. | WELFIDE CORPORATION (JP) | 2001-04-24 | — | — | US | disclosed |
| EP-0995746-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DISEASES ATTRIBUTABLE TO INFECTION WITH HELICOBACTERS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058923-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | CCR1, MALT1, REL | DRD4 3922/4885CYP1A2 149/4885CYP3A4 1026/4885 |
| US-20070185153-A1 | COMPOUNDS | NRDC, NISCH, MRPL21 | DRD4 1321/4885CYP1A2 1281/4885CYP3A4 398/4885 |
| US-20050222147-A1 | Process for the preparation of morpholine derivatives and intermediates therefore | NISCH, MYO3B, CYP11B2 | DRD4 210/4885CYP1A2 7/4885CYP3A4 11/4885 |
| US-20060079525-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | ARG1, ARG2, NFKBIA | DRD4 2049/4885CYP1A2 67/4885CYP3A4 1012/4885 |
| US-20100184751-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | SDHA, SDHB, NNT | DRD4 2221/4885CYP1A2 217/4885CYP3A4 162/4885 |
| US-20150322043-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | TPM3, MUSK, TPM4 | DRD4 4847/4885CYP1A2 3621/4885CYP3A4 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.